Factors associated with self-rated health in people with late-stage parkinson’s and cognitive impairment
-
Published:2024-06-18
Issue:9
Volume:33
Page:2439-2452
-
ISSN:0962-9343
-
Container-title:Quality of Life Research
-
language:en
-
Short-container-title:Qual Life Res
Author:
Pigott Jennifer S.ORCID, Armstrong MeganORCID, Davies NathanORCID, Davis DanielORCID, Bloem Bastiaan R.ORCID, Lorenzl StefanORCID, Meissner Wassilios G.ORCID, Odin PerORCID, Ferreira Joaquim J.ORCID, Dodel RichardORCID, Schrag AnetteORCID
Abstract
Abstract
Purpose
To investigate the contributors to self-rated health in people with late-stage Parkinson’s disease (PD) and cognitive impairment.
Methods
A secondary analysis of baseline data from the international Care of Late-Stage Parkinsonism (CLaSP) cohort study was conducted. Participants with PD and either dementia or mild cognitive impairment or MMSE < 24/30 in the absence of major depression were included if they had completed the EQ-5D-3L assessment (n = 277). Factors associated with self-rated health (EQ-5D-3L Index and Visual Analogue Scale) were investigated through multivariable linear regression.
Results
More severe PD (motor and non-motor) was associated with worse self-rated health. The EQ-5D-3L dimensions of Mobility, Self-Care and Usual Activities were almost universally affected; the latter two particularly severely. Being unable to perform usual activities or having moderate to extreme anxiety or depression were significantly associated with EQ-5D-3L Visual Analogue Scale, suggesting these are particularly valued. Worse motor impairment and function and the non-motor symptom domains of mood, perception, sexual function, and miscellaneous (e.g., pain) were associated with worse self-rated health, whereas greater burden of gastrointestinal symptoms was associated with better self-rated health in multivariate analysis. Better self-rated health was associated with recent PD nurse consultation, and higher doses of dopaminergic medication.
Conclusion
Improvement of activities of daily living, mood and anxiety should be prioritised in clinical practice, with consideration of perception and sexual function in this population. Recent nurse consultations and higher antiparkinsonian doses are associated with better self-rated health, suggesting there is no room for a therapeutic nihilism in this population of people within a complex phase of PD.
Funder
Rosetrees Trust Royal College of Physicians European Commission
Publisher
Springer Science and Business Media LLC
Reference69 articles.
1. Ray Dorsey, E., Elbaz, A., Nichols, E., Abd-Allah, F., Abdelalim, A., Adsuar, J. C., Ansha, M. G., Brayne, C., Choi, J. Y. J., Collado-Mateo, D., Dahodwala, N., Do, H. P., Edessa, D., Endres, M., Fereshtehnejad, S. M., Foreman, K. J., Gankpe, F. G., Gupta, R., Hankey, G. J., … Murray, C. J. L. (2018). Global, regional, and national burden of parkinson’s disease, 1990–2016: A systematic analysis for the global burden of disease study 2016. Lancet Neurology, 17, 939–953. PMID: 30287051. 2. Coelho, M., & Ferreira, J. J. (2012). Late-stage parkinson disease. Nature Reviews. Neurology, 8, 435–442. 3. Hely, M. A., Reid, W. G. J., Adena, M. A., Halliday, G. M., & Morris, J. G. L. (2008). The Sydney multicenter study of parkinson’s disease: The inevitability of dementia at 20 years. Movement Disorders, 23, 837–844. PMID: 18307261. 4. Aarsland, D., Batzu, L., Halliday, G. M., Geurtsen, G. J., Ballard, C., Chaudhuri, K. R., & Weintraub, D. (2021). Parkinson disease-associated cognitive impairment. Nature Reviews Disease Primers, 7(1), 47. 5. Kempster, P. A., Williams, D. R., Selikhova, M., Holton, J., Revesz, T., & Lees, A. J. (2007). Patterns of levodopa response in parkinson’s disease: A clinico-pathological study. Brain, 130, 2123–2128. PMID: 17586867.
|
|